Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 12, 2016, Pages 1129-1139

  Di Mauro, S ^a   Ragusa, M ^b   Urbano, F ^a   Filippello, A ^a   Di Pino, A ^a   Scamporrino, A ^a   Pulvirenti, A ^a   Ferro, A ^a   Rabuazzo, A M ^a   Purrello, M ^b   Purrello, F ^a   Piro, S ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Department Gian Filippo Ingrassia   (Italy)

Author keywords

FFAs; HepG2; microRNAs; NAFLD; NASH

Indexed keywords

BIOLOGICAL MARKER; CD36 ANTIGEN; CERAMIDE; DIACYLGLYCEROL; FATTY ACID; FATTY ACID TRANSPORTER; INSULIN RECEPTOR SUBSTRATE 1; MICRORNA; MICRORNA 1226; MICRORNA 1255B; MICRORNA 126; MICRORNA 1290; MICRORNA 1303; MICRORNA 148B; MICRORNA 150; MICRORNA 204; MICRORNA 214; MICRORNA 223; MICRORNA 27A; MICRORNA 31; MICRORNA 320B; MICRORNA 483 3P; MICRORNA 529; MICRORNA 744; MICRORNA 92A 1; MICRORNA 99B; OLEIC ACID; PALMITIC ACID; PROTEIN KINASE B; UNCLASSIFIED DRUG; UNINDEXED DRUG; COENZYME A LIGASE; GENETIC MARKER; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; LONG-CHAIN-FATTY-ACID-COA LIGASE;

APOPTOSIS; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DEREGULATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FATTY ACID METABOLISM; FLUOROMETRY; GENE EXPRESSION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT RISK; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOLOGY; CELL SURVIVAL; CHEMICALLY INDUCED; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC MARKER; GENETICS; HEP-G2 CELL LINE; LIVER; LIVER CELL; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTOR;

ANTIGENS, CD36; CELL SURVIVAL; CERAMIDES; COENZYME A LIGASES; COMPUTATIONAL BIOLOGY; DIGLYCERIDES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENETIC MARKERS; HEP G2 CELLS; HEPATOCYTES; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; LIVER; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; OLEIC ACID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PALMITIC ACID; PHOSPHORYLATION; PROTEIN INTERACTION MAPS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84994475836     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.08.004     Document Type: Article

References (53)

1. [1] Dowman, J.K., Tomlinson, J.W., Newsome, P.N., Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 33 (2011), 525–540.
2. [2] Neuschwander-Tetri, B.A., Caldwell, S.H., Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37 (2003), 1202–1219.
3. [3] Wieckowska, A., McCullough, A.J., Feldstein, A.E., Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46 (2007), 582–589.
4. [4] Sobolewski, C., Calo, N., Portius, D., Foti, M., MicroRNAs in fatty liver disease. Semin Liver Dis 35 (2015), 12–25.
5. [5] Rottiers, V., Najafi-Shoushtari, S.H., Kristo, F., Gurumurthy, S., Zhong, L., Li, Y., et al. MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb Symp Quant Biol 76 (2011), 225–233.
6. [6] Mi, S., Zhang, J., Zhang, W., Huang, R.S., Circulating microRNAs as biomarkers for inflammatory diseases. Microrna 2 (2013), 63–71.
7. [7] Chu, J.H., Wang, H., Ye, Y., Chan, P.K., Pan, S.Y., Fong, W.F., et al. Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells. World J Gastroenterol 17 (2011), 2379–2388.
8. [8] Kwan, H.Y., Fong, W.F., Yang, Z., Yu, Z.L., Hsiao, W.L., Inhibition of DNA-dependent protein kinase reduced palmitate and oleate-induced lipid accumulation in HepG2 cells. Eur J Nutr 52 (2013), 1621–1630.
9. [9] Ricchi, M., Odoardi, M.R., Carulli, L., Anzivino, C., Ballestri, S., Pinetti, A., et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 24 (2009), 830–840.
10. [10] Gomez-Lechon, M.J., Donato, M.T., Martinez-Romero, A., Jimenez, N., Castell, J.V., O'Connor, J.E., A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165 (2007), 106–116.
11. [11] Akazawa, Y., Cazanave, S., Mott, J.L., Elmi, N., Bronk, S.F., Kohno, S., et al. Palmitoleate attenuates palmitate-induced Bim and PUMA upregulation and hepatocyte lipoapoptosis. J Hepatol 52 (2010), 586–593.
12. [12] Alaimo, S., Giugno, R., Acunzo, M., Veneziano, D., Ferro, A., Pulvirenti, A., Post-transcriptional knowledge in pathway analysis increases the accuracy of phenotypes classification. Oncotarget, 2016.
13. [13] Ragusa, M., Statello, L., Maugeri, M., Barbagallo, C., Passanisi, R., Alhamdani, M.S., et al. Highly skewed distribution of miRNAs and proteins between colorectal cancer cells and their exosomes following Cetuximab treatment: biomolecular, genetic and translational implications. Oncoscience 1 (2014), 132–157.
14. [14] Greenspan, P., Mayer, E.P., Fowler, S.D., Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol 100 (1985), 965–973.
15. [15] Yao, H.R., Liu, J., Plumeri, D., Cao, Y.B., He, T., Lin, L., et al. Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res 3 (2011), 284–291.
16. [16] Urbano, F., Filippello, A., Di Pino, A., Barbagallo, D., Di Mauro, S., Pappalardo, A., et al. Altered expression of uncoupling protein 2 in GLP-1-producing cells after chronic high glucose exposure: implications for the pathogenesis of diabetes mellitus. Am J Physiol Cell Physiol 310 (2016), C558–C567.
17. [17] Piro, S., Maniscalchi, E.T., Monello, A., Pandini, G., Mascali, L.G., Rabuazzo, A.M., et al. Palmitate affects insulin receptor phosphorylation and intracellular insulin signal in a pancreatic alpha-cell line. Endocrinology 151 (2010), 4197–4206.
18. [18] Piro, S., Mascali, L.G., Urbano, F., Filippello, A., Malaguarnera, R., Calanna, S., et al. Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (alpha-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cells. PLoS One, 9, 2014 e90093.
19. [19] Vallelunga, A., Ragusa, M., Di Mauro, S., Iannitti, T., Pilleri, M., Biundo, R., et al. Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and multiple system atrophy. Front Cell Neurosci, 8, 2014, 156.
20. [20] Barbagallo, D., Piro, S., Condorelli, A.G., Mascali, L.G., Urbano, F., Parrinello, N., et al. miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic alpha cells to cytokine-induced apoptosis as compared to beta cells. BMC Genomics, 14, 2013, 62.
21. [21] Ragusa, M., Barbagallo, C., Statello, L., Caltabiano, R., Russo, A., Puzzo, L., et al. miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: pathological and diagnostic implications. Cancer Biol Ther 16 (2015), 1387–1396.
22. [22] Zhou, J., Febbraio, M., Wada, T., Zhai, Y., Kuruba, R., He, J., et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 134 (2008), 556–567.
23. [23] Chavez, J.A., Summers, S.A., A ceramide-centric view of insulin resistance. Cell Metab 15 (2012), 585–594.
24. [24] Wilson, C.G., Tran, J.L., Erion, D.M., Vera, N.B., Febbraio, M., Weiss, E.J., Hepatocyte- specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice. Endocrinology 157 (2016), 570–585.
25. [25] Mashek, D.G., Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr 4 (2013), 697–710.
26. [26] Fitzpatrick, E., Dhawan, A., Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 20 (2014), 10851–10863.
27. [27] Wen, D., Qiao, P., Wang, L., Circulating microRNA-223 as a potential biomarker for obesity. Obes Res Clin Pract 9 (2015), 398–404.
28. [28] Vickers, K.C., Landstreet, S.R., Levin, M.G., Shoucri, B.M., Toth, C.L., Taylor, R.C., et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A 111 (2014), 14518–14523.
29. [29] Sun, X., Zhang, M., Sanagawa, A., Mori, C., Ito, S., Iwaki, S., et al. Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol. Thromb J, 10, 2012, 16.
30. [30] Krause, B.J., Carrasco-Wong, I., Dominguez, A., Arnaiz, P., Farias, M., Barja, S., et al. Micro-RNAs Let7e and 126 in plasma as markers of metabolic dysfunction in 10 to 12 years old children. PLoS One, 10, 2015 e0128140.
31. [31] Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., et al. Plasma VmicroRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107 (2010), 810–817.
32. [32] Karolina, D.S., Tavintharan, S., Armugam, A., Sepramaniam, S., Pek, S.L., Wong, M.T., et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 97 (2012), E2271–E2276.
33. [33] Vickers, K.C., Palmisano, B.T., Shoucri, B.M., Shamburek, R.D., Remaley, A.T., MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13 (2011), 423–433.
34. [34] Rayner, K.J., Moore, K.J., MicroRNA control of high-density lipoprotein metabolism and function. Circ Res 114 (2014), 183–192.
35. [35] Wagner, J., Riwanto, M., Besler, C., Knau, A., Fichtlscherer, S., Röxe, T., et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler Thromb Vasc Biol 33 (2013), 1392–1400.
36. [36] Tan, Y., Ge, G., Pan, T., Wen, D., Gan, J., A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One, 9, 2014, e105192.
37. [37] Zhu, H., Shyh-Chang, N., Segre, A.V., Shinoda, G., Shah, S.P., Einhorn, W.S., et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 147 (2011), 81–94.
38. [38] Hung, T.M., Ho, C.M., Liu, Y.C., Lee, J.L., Liao, Y.R., Wu, Y.M., et al. Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma. PLoS One, 9, 2014 e89446.
39. [39] Goedeke, L., Vales-Lara, F.M., Fenstermaker, M., Cirera-Salinas, D., Chamorro-Jorganes, A., Ramírez, C.M., et al. A regulatory role for microRNA 33* in controlling lipid metabolism gene expression. Mol Cell Biol 33 (2013), 2339–2352.
40. [40] Meerson, A., Traurig, M., Ossowski, V., Fleming, J.M., Mullins, M., Baier, L.J., Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-alpha. Diabetologia 56 (2013), 1971–1979.
41. [41] Yang, Z., Bian, C., Zhou, H., Huang, S., Wang, S., Liao, L., et al. MicroRNA hsa-miR-138 inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells through adenovirus EID-1. Stem Cells Dev 20 (2011), 259–267.
42. [42] Ferland-McCollough, D., Fernandez-Twinn, D.S., Cannell, I.G., David, H., Warner, M., Vaag, A.A., et al. Programming of adipose tissue miR-483-3p and GDF-3 expression by maternal diet in type 2 diabetes. Cell Death Differ 19 (2012), 1003–1012.
43. [43] Cheung, O., Puri, P., Eicken, C., Contos, M.J., Mirshahi, F., Maher, J.W., et al. Nonalcoholic steatohepatitis is associated with altered hepatic Micro-RNA expression. Hepatology 48 (2008), 1810–1820.
44. [44] Browning, J.D., Horton, J.D., Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004), 147–152.
45. [45] Farrell, G.C., van Rooyen, D., Gan, L., Chitturi, S., NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 6 (2012), 149–171.
46. [46] Arendt, B.M., Comelli, E.M., Ma, D.W., Lou, W., Teterina, A., Kim, T., et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology 61 (2015), 1565–1578.
47. [47] Gupte, A.A., Liu, J.Z., Ren, Y., Minze, L.J., Wiles, J.R., Collins, A.R., et al. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 52 (2010), 2001–2011.
48. [48] Kohjima, M., Enjoji, M., Higuchi, N., Kato, M., Kotoh, K., Yoshimoto, T., et al. Reevaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 20 (2007), 351–358.
49. [49] Ai, Z.L., Zhu, C.H., Min, M., Wang, J., Lan, C.H., Fan, L.L., et al. The role of hepatic liver X receptor alpha- and sterol regulatory element binding protein-1c-mediated lipid disorder in the pathogenesis of nonalcoholic steatohepatitis in rats. J Int Med Res 39 (2011), 1219–1229.
50. [50] Dorn, C., Riener, M.O., Kirovski, G., Saugspier, M., Steib, K., Weiss, T.S., et al. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol 3 (2010), 505–514.
51. [51] Vazquez-Chantada, M., Gonzalez-Lahera, A., Martinez-Arranz, I., Garcia-Monzon, C., Regueiro, M.M., Garcia-Rodriguez, J.L., et al. Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease. Hepatology 57 (2013), 505–514.
52. [52] Nagaya, T., Tanaka, N., Kimura, T., Kitabatake, H., Fujimori, N., Komatsu, M., et al. Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy. BBA Clin 3 (2015), 168–174.
53. [53] Maruyama, H., Kiyono, S., Kondo, T., Sekimoto, T., Yokosuka, O., Palmitate-induced regulation of PPARgamma via PGC1alpha: a mechanism for lipid accumulation in the liver in nonalcoholic fatty liver disease. Int J Med Sci 13 (2016), 169–178.